| Nicholas Andrew Pagliari, CRNA | |
|
2407 S Congress Ave # E499, Austin, TX 78704-5505 | |
| (615) 332-2941 | |
| Not Available |
| Full Name | Nicholas Andrew Pagliari |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 7 Years |
| Location | 2407 S Congress Ave # E499, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033627260 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Northwest Llc | 7618908484 | 76 |
News Archive
Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).
Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.
Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.
Baxter International Inc. announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.
› Verified 2 days ago
| Entity Name | University Anesthesiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841217817 PECOS PAC ID: 6901702869 Enrollment ID: O20031210000967 |
News Archive
Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).
Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.
Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.
Baxter International Inc. announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.
› Verified 2 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).
Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.
Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.
Baxter International Inc. announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.
› Verified 2 days ago
| Entity Name | Anesthesia Associates Northwest Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548281751 PECOS PAC ID: 7618908484 Enrollment ID: O20050822001459 |
News Archive
Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).
Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.
Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.
Baxter International Inc. announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Andrew Pagliari, CRNA 2407 S Congress Ave # E499, Austin, TX 78704-5505 Ph: (615) 332-2941 | Nicholas Andrew Pagliari, CRNA 2407 S Congress Ave # E499, Austin, TX 78704-5505 Ph: (615) 332-2941 |
News Archive
Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).
Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.
Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.
Baxter International Inc. announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.
› Verified 2 days ago
Denise Leger, RN Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 8140 N Mopac Expy Ste 3-210, Austin, TX 78759 Phone: 512-343-2292 Fax: 512-343-2745 | |
Cherese Wheelock, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy, Suite 570, Austin, TX 78705 Phone: 512-454-2554 | |
Donna M Landry, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2304 Hancock Dr Ste 4, Austin, TX 78756 Phone: 512-407-8444 Fax: 512-407-8097 | |
Jeremy Frank Briggs, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy, Suite 570, Austin, TX 78705 Phone: 512-454-2554 | |
Genevieve L Woolsey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy, Suite 570, Austin, TX 78705 Phone: 512-454-2554 | |
Dania Northcutt, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy, Suite 570, Austin, TX 78705 Phone: 512-454-2554 | |
Mr. Matthew Jeffrey Doherty, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 12221 N Mopac Expy, Austin, TX 78758 Phone: 512-901-1000 |